| Name | Title | Contact Details |
|---|
Abundant Nursing Solutions is a company that specializes in providing quality care measures, Value Based Purchasing, Star Ratings, and Quality control measures for home health agencies. They offer Medicare certified Quality Assurance coding and complia...
Founded in 2009, Nashville-based Applied Health Analytics, LLC provides software and consulting services to health systems interested in supporting primary care strategies, growing revenue, improving reimbursement quality and creating population-health management initiatives. A joint-venture partner with Vanderbilt University Medical Center`s Dayani Center for Health and Wellness, Applied Health Analytics advances the role of hospitals and health systems as they engage employers to enhance individual health and increase share among commercial populations.
PDI Inc. is a provider of contract sales teams to pharmaceutical companies, offering a range of sales support services.
Our Partnership Health Centers offer customized, patient-centered, cost-effective health programs built on the wisdom of coordinated care. We believe in an effective, medical-home partnership strategy to cut the price of medical expenses by promoting better health outcomes. No one in the industry offers more services at the same location, with same-day appointments and no co-pays! We have data to prove our company motto: “Lower Costs Through Better Health”.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.